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Abstract: The term signal transduction includes the interaction of external signals that are driven by hormones, growth 
factors, chemokines, cytokines and small molecules such as ATP in order to receive a cellular response. These 
responses in turn effect gene transcription and translation, cell division, survival and death upon many signaling 
networks related with malignancies. Since almost all diseases exhibit dysfunctional aspects of the signaling pathways, 
drug discovery studies in means of signal transduction therapies have an accelerating importance including chronic 
leukemias. 
Among chronic leukemias, chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML) are being 
investigated extensively for abnormalities of cellular signaling pathways. This review focuses on targeting B-cell antigen 
receptor (BCR) signaling and Wnt/-Catenin/LEF-1 signaling pathways and their inhibitors that provided new 
opportunities for development of more effective therapies for CLL. Besides this, signaling network systems such as 
RAS/RAF/MAPK and JAK/STAT will be discussed that contribute high oncogenic activity of BCR-ABL1 oncoprotein in 
CML. Finally the molecular targets in treatment duration with clinical insights will be discussed. 
Keywords: Chronic lymphocytic leukemia, Chronic myeloid leukemia, Signal transduction pathways, Treatment. 
INTRODUCTION 
Chronic lymphocytic leukemia (CLL) is the most 
common type of lymphoid malignancy in adults aging 
between 65 -72 years and represents 11 % of all blood 
cancer types [1]. CLL is characterized by the clonal 
proliferation and accumulation of mature CD5+ B cells 
in the peripheral blood, bone marrow and lymphoid 
organs [2]. CLL is a heterogeneous disease and can be 
classified into two major groups according to the 
mutational status of Ig V: somatically unmutated Ig V 
genes (U-CLL) and mutated Ig V genes (M-CLL). U-
CLL originates from naive B-cells in aim to compete 
against common pathogens. About 50% of CLL 
diagnosed patients’ leukemic cells have somatic hyper 
mutation in rearranged immunoglobulin heavy-chain 
variable region genes; which in turn results in a more 
favorable clinical outcome. Immunoglobulin gene 
mutational status and prognosis of CLL can be 
associated due to median survival time: while median 
survival is determined as 8 years for patients with 
unmutated IgVH genes; approximately 25 years of 
survival is detected in patients carrying mutated IgVH 
genes [3].  
The leukemic transformation starts by genetic 
modifications; especially deletion on 13
th
 chromosome 
[del(13q14)] which in turn causes deletion of some 
specific microRNAs (miRNA) and strengthens B cells 
by avoiding apoptotic cell death [4-5]. Besides this, [del 
(11q)], [del (17p)] and trisomy 12 may occur later in the 
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course of the disease and these alterations predict a 
worse clinical outcome such as short survival time and 
gain of resistance to conventional DNA-damaging 
chemotherapies such as alkylating agents, purine 
analogs and rituximab [6-7]. In addition, genome wide 
sequencing has revealed new somatic gene mutations 
occurring in CLL cells; affecting NOTCH1, MYD88, 
TP53, ATM, and SF3B1 genes which have prognostic 
impact [8]. Today, for early diagnosis of CLL in which 
patients suffer by an aggressive form of the disease; is 
guided by some different molecular markers such as 
mutation status of IgHV gene [9], the cell surface 
expression of CD38 [10] and CD49d [11] and 
intracellular presence of ZAP-70 ( -chain-associated 
protein kinase 70 kDa) that exhibits shorter survival. 
Since the mutational status of IgHV gene was an 
important prognostic factor in CLL, the expression of 
ZAP-70 in CLL cells and IgVH mutational status, 
disease progression and survival interaction was 
examined in order to find a correlation. The authors 
detected ZAP-70 expression in cells of T-cell lineage 
and in leukemic cells from 32 of 56 (57%) patients with 
CLL. Besides this, in all patients in whom at least 20 
percent of the leukemic cells were positive for ZAP-70, 
IgVH was unmutated, whereas IgVH mutations were 
found in 21 of 24 patients (87.5%) in whom less than 
20 percent of the leukemic cells were positive for ZAP-
70. This refers that ZAP-70 expression was correlated 
with IgVH mutational status, disease progression, and 
survival [12].  
Sufficient progress in molecular biology has resulted 
in a better characterization and understanding of the 
pathogenesis and prognosis of CLL. It is now clear that 
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the origin, development and survival of CLL cells are 
dependent on microenvironment that includes T cells, 
macrophages or stromal follicular dendritic cells [13]. 
This microenvironment provides essential proteins 
such as cytokines, chemokines and angiogenic factors 
for activation of crucial survival and proliferative 
signaling pathways of transformed cells [14]. The 
mission of the signal transduction therapy is to turn the 
differences of transformed cell into normal cell or 
induce leukemic cell apoptosis. This review focuses on 
targeting signal transduction pathways such as B-cell 
antigen receptor (BCR) signaling and Wnt/-Catenin/ 
LEF-1 signaling pathways and inhibitors such as 
Dasatinib, Fostamatinib, Idelalisib, Perifosine, Evero- 
limus and Ibrutinib that provided new opportunities for 
development of more effective therapies in CLL. 
Chronic myeloid leukemia (CML) is characterized by 
the presence of resiprocal translocation between 
chromosomes 9 and 22; referred as Philadelphia (Ph 
+). CML displays three phases of the disease by 
progressing from an initial chronic phase to accelerated 
and blast crisis phases. Also, increased BCR-ABL1 
expression due to high tyrosine kinase activity is seen 
in the leukemic cells as a result of genomic instability in 
Ph (+) cells [15].  
Early CML treatment started with x-radiation 
applications and conventional chemotherapeutic drugs 
such as hydroxyurea or busulfan. Although these 
strategies helped to decelerate myeloid tissue 
enlargement and increase life expectancy in chronic 
phase, they caused no additional benefit in blastic 
duration of the illness. One of the most important 
improvements was achieved by allogeneic stem cell 
transplantation application. About half of the patients 
who were convenient for transplantation –especially 
under age of 40- became both Philadelphia and BCR-
ABL1 negative and were finally cured [16]. The second 
climax of the therapy was the usage of interferon-alfa 
that provided a considerable survival length over 
conventional chemotherapy agents [17]. The most 
encouraging therapy strategy was developed by the 
discovery of the first signal transduction inhibitor; a 
class of small molecules referred as tyrosine kinase 
inhibitor (TKI): Imatinib Mesylate (Glivec or Gleevec, 
Novartis). It prevents the BCR-ABL1 oncoprotein from 
exerting its role in the oncogenic pathway; besides, 
directly inhibits the constitutive tyrosine kinase activity 
by blocking ATP binding site. This results in the 
modification of the function of various genes involved in 
cell cycle control, cell adhesion, cell proliferation and 
survival, cytoskeleton organization and finally in the 
apoptotic death of Ph (+) cells [18-19]. Next, other 
second generation TKIs were developed, namely 
Nilotinib (Tasigna, Novartis), Dasatinib (Sprycel, 
Bristol-Myers Squibb), Bosutinib (Busulif, Pfizer) and 
lastly Ponatinib (Iclusig, Ariad) [20-23]. However, there 
are still some limitations for the usage of these TKIs in 
clinic. For example, although imatinib is efficient in the 
cure of chronic phase, it is not curative enough in 
blastic crisis phase [24]. Besides, both first and second 
line TKIs might lack the efficient therapy either for 
developing required resistance to therapy through 
ABL1 gain of mutations or other mechanisms [25]. 
These common recurrent mutations in tyrosine kinases 
define the molecular biology of CML by activating 
signal transduction pathways that are critical for 
leukemic cell growth, proliferation and survival. The 
quest for identification of the specific signaling proteins 
involved in CML and understanding the biological 
importance of the signal transduction pathways has 
constructed the signal transduction therapies. Since 
BCR-ABL1 exerts its oncogenic activity through 
signaling network systems such as RAS/RAF/MAPK 
and JAK/STAT, these pathways will be discussed 
specifically. 
1. CHRONIC LYMPHOCYTIC LEUKEMIA 
1.1. BCR Signaling 
Constitutively active BCR signaling is critical for 
chronic lymphocytic leukemia cell growth and survival. 
BCR pathway is aberrantly or excessively activated in 
CLL cells and therefore represents a promising target 
for therapeutic intervention. Normal B lymphocytes 
receive two types of signals from their BCRs. In normal 
functioning B lymphocytes, binding of BCR by an 
external antigen triggers a signaling pathway that 
controls proliferation, survival, differentiation, apoptosis, 
anergy and antibody production [26]. Activated BCR in 
the signaling pathway recruits spleen tyrosine kinase 
(SYK) and the SRC kinase LYN that phosphorylate 
immunoreceptor tyrosine-based activation (ITAM) 
motifs on the cytoplasmic domains of the Ig co-
receptors CD79A and CD79B. Phosphorylation results 
in recruitment and activation of Bruton’s tyrosine kinase 
(BTK) and PI3K, subsequently activating many 
downstream targets including AKT/mammalian target 
of rapamycin (mTOR), NF-B, and ERK pathways. The 
basic interactions of signaling pathways involved in 
CLL are given in Figure 1. 
The second type of signal occurs in the absence of 
an external ligand and termed as “tonic BCR signal”. 
The role of this signal has still not been fully 
understood in normal B cell biology; but, recent studies 
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suggest that it is essential for both survival of mature B 
cells and normal B cell development with correct 
maturation process. As aberrantly activated BCR 
signaling plays a key role in the pathogenesis of CLL 
by promoting leukemia cell survey in both ligand-
induced and nonligand-dependent events, blocking 
BCR signaling via various components holds great 
therapeutic potentials in CLL [27]. 
 
Figure 1: Basic signaling interactions in CLL. 
1.2. Targeting BCR Signaling by Protein Tyrosine 
Kinases 
The four proximal protein tyrosine kinases 
mediating BCR signaling LYN, SYK, PI3K, and BTK 
are all found to be over-expressed and constitutively 
activated in CLL cells compared to normal B 
lymphocytes. These upstream kinases can be targeted 
by small molecule inhibitors which are being studied in 
preclinical and clinical studies. These agents are 
discussed below. 
1.2.1. Targeting LYN and LYN Inhibitors with 
Clinical Experience 
LYN initiates BCR signaling by phosphorylating 
ITAMs in the Ig and Ig chains of the BCR. The 
phosphorylated ITAMs recruit SYK kinase, which then 
gains activation through SRC-family kinase-dependent 
phosphorylation at Y352 and trans-autophosphorylation 
at YY525/526. LYN not only phosphorylates and 
thereby activates SYK; but also activates phos- 
phatases that in turn inhibit BCR signal transduction. 
Thus, LYN functions as both a positive and negative 
regulator of BCR signaling [28]. 
Targeting LYN with SRC-family kinase inhibitors 
such as PP2 and Dasatinib resulted in induced 
leukemic cell apoptosis [29-30]. But, it is still unclarified 
whether the cytotoxic effect of these agents is due to 
inhibition of LYN or inhibition of related kinases. In 
clinics, a phase 2 trial study (including 15 
relapsed/refractory CLL patients), the cases were 
treated with 140 mg dasatinib which resulted with 20% 
overall response rate and progression-free survival 
length of 7.5 months [31].  
1.2.2. Targeting SYK and SYK Inhibitors with 
Clinical Experience 
Following antigen binding to BCR, LYN phosphoryl- 
ates SYK that results in amplification in initial BCR 
signal and activates the downstream signaling cas- 
cade. Besides this, SYK is also involved in chemokine, 
integrin and Fc-receptor signaling [32]. SYK is 
constitutively phosphorylated on the Y352 residue of 
CLL cells; but, there is no correlation between the 
degree of SYK activation and clinical or biologic 
features of more aggressive disease [33].  
Targeting SYK induces moderate levels of apop- 
tosis in unstimulated CLL cells, further suggesting that 
the cell autonomous BCR signal increases leukemic 
cell survival [34]. SYK inhibitor Fostamatinib; R788, an 
oral pro-drug of the active metabolite R406 is an ATP-
competitive kinase inhibitor that also inhibits a number 
of other kinases. Treatment of CLL cells with 
Fostamatinib results in blockage of transduction for 
extrinsic antigen-dependent BCR signals, inhibition in 
integrin signaling and also reduction in proliferation and 
survival of the malignant B cells with induced apoptosis 
[35]. In clinics, fostamatinib was tested in a phase 1/2 
trial of relapsed or refractory non-Hodgkin lymphoma 
and CLL which in turn resulted with 55% achieved 
partial response that was considered as highest 
response rate in CLL patients [36]. Fostamatinib follow-
up is not continuing today because the company is 
producing the agent as a rheumatoid arthritis treatment 
strategy. Although some clinical studies are going on 
for treatment of diffuse large B cell lymphoma, it is not 
clear whether fostamatinib can take place in CLL 
therapy. Nowadays two novel highly selective Syk 
inhibitors, PRT318 and P505-15 are being studied and 
expected to take place in clinics for CLL treatment [37]. 
1.2.3. Targeting PI3K/AKT/mTOR and Their 
Inhibitors with Clinical Experience 
PI3K is a key downstream mediator of BCR 
signaling. CLL cells generally express high levels of 
active PI3K and consistent activation of this pathway 
increases their proliferative capacity and survival. 
Among several PI3K isoforms, PI3K is the specifically 
expressed one in leukocytes and consists of two 
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components as regulatory p85 and catalytic p110 
subunits. When p85 binds to phosphotyrosine motifs on 
receptor tyrosine kinases or adaptor molecules, p110 
becomes activated and phosphorylates phospha- 
tidylinositol 4,5-bisphosphate (PIP2) to generate PIP3. 
PIP3 carries cytoplasmic kinases BTK and AKT to 
cellular membrane in order to form a functional 
signaling complex. AKT is responsible for effecting 
PI3K and after translocating onto cellular membrane, 
AKT membrane is activated by the mammalian target 
of rapamycin complex 2 (mTORC2). Activated AKT 
then phosphorylates a number of downstream targets 
that are essential for B-cell proliferation and survival 
[38]. 
Inhibition of PI3K activity by LY294002 inhibitor 
induced apoptosis of CLL cells; however it has been 
obstructed due to toxicity [39]. Idelalisib [(GS-1101) or 
(CAL-101)] is a highly selective inhibitor of the PI3K 
which induces apoptosis in CLL cells in vitro and 
inhibits the assistive effect of many microenvironmental 
factors and inhibits survival signals generated by 
triggering of the BCR [40]. To date clinical trials CAL-
101 of has not been finished but promising clinical 
activity was reported at the American Society of 
Hematology (ASH) 2010 scientific meeting as 33% 
partial response in CLL patients [41]. Updated data on 
54 patients were presented at the American Society of 
Clinical Oncology (ASCO) annual meeting in 2011 as 
Phase I study; but overall response rate was reported 
as 26% [42]. Since then, combination studies 
accelerated and strong rational was provided for the 
combination of PI3K inhibitors and histone deacetylase 
inhibitor (HDI) in CLL clinic [43]. 
Since AKT is activated in CLL; it is reported that 
inhibition of this activation by selective inhibitor Akti-1/2 
induced apoptosis of CLL cells in vitro [44]. Another 
study showed that AKT inhibitor AiX induced apoptosis 
preferentially in IgVH unmutated CLL cells [45]. Finally, 
Perifosine is currently being tested in a phase 2 trial in 
patients with relapsed/refractory CLL. They reported 
that Perifosine was cytotoxic to CLL cells in vitro, and 
largely induced stabilized disease in vivo, with an AKT-
independent mechanism [46]. 
mTOR is an ubiquitously expressed serine/ 
threonine kinase involved in cellular growth and 
proliferation and also functions as a downstream 
mediator of BCR signaling through PI3K/AKT pathway 
[47]. mTOR also regulates cell cycle transition from G1 
to S phase [48]. Rapamycin (sirolimus) is an 
immunosuppressive agent and also exhibits growth 
inhibitory and proapoptotic effect upon lymphocytes 
[49]. Preclinical data showed that, while rapamycin 
treated cells lacking functional p53 underwent 
apoptosis; p53 wild type cells were arrested in G1 
phase but remained viable. So, as a treatment option, 
CLL patients lacking p53 function [(del (17p) and p53 
mutations] will show worse prognosis in clinics [50]. 
The importance of mTOR signaling in CLL has been 
demonstrated in Eμ-TCL1 transgenic mouse model; 
where rapamycin slowed leukemia growth and 
prolonged the survival of the treated animals [51]. In 
clinics, a pilot trial of Everolimus (RAD001) in patients 
with advanced B-CLL exhibited some degree of 
activity, but was stopped earlier because of toxicity 
concerns [52]. Later on, the second trial was done with 
a larger phase II study of everolimus and finally 18% of 
CLL patients achieved a partial response and showed 
signs of severe toxicity from immunosuppression and 
infectious complications [53]. In the third trial, the 
immunosuppressive effect of everolimus in CLL was 
substantiated also severe infectious complications 
were reported [54]. However, use of everolimus in 
combination therapy (idelalisib, alemtuzumab, pano- 
binostat, bortezomib, lapitinib or sorafenib) for CLL will 
await further clinical trials in order to handle the 
immunosuppressive effect of everolimus in CLL [55].  
1.2.4. Targeting BTK and BTK Inhibitors with 
Clinical Experience 
BTK is a cytoplasmic tyrosine kinase belonging to 
Tec family and serves an essential role in B-cell 
development and BCR signaling. Loss of BTK causes 
X-linked agammaglobulinemia (Bruton’s agamma- 
globulinemia), which is characterized by decreased 
immunoglobulin production and absence of B cells [56]. 
Two basic models have been proposed for activation of 
BTK in CLL. In the first model, BCR cross-linking 
promotes LYN activation, which in turn recruits BTK to 
the plasma membrane via PIP3 that is generated by 
PI3K. Then, BTK is phosphorylated by SRC family 
kinases at Y551 and autophosphorylated at Y223 
residue of BTK [57]. In the second model, BTK is 
activated independent from PI3K. This activation leads 
to calcium mobilization (by activation of PLC-2); which 
in turn activate the transcription factor NF-B. Active 
NF-B induces antiapoptotic gene BCL-XL expression 
and increases cell survival by induction of cyclin D2 
[58].  
Since BTK is found to be significantly overex- 
pressed in CLL as compared to normal B cells; 
targeting BTK is a promising therapeutic approach for 
CLL treatment. In preclinical studies, BTK inhibitor 
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Ibrutinib (PCI-32765) demonstrated its selectivity 
towards tumor B cells by inhibiting BTK phosphoryl- 
ation (by covalently binding to its cysteine-481 residue), 
demolishing downstream survival molecules (ERK1/2, 
PI3K and NF-B), inhibiting BCR and directly inducing 
modest levels of apoptosis in CLL cells [59]. In clinics, 
the initial phase I study with this agent examined in 
CLL patients resulted with 60% overall response rate, 
treatment was well tolerated and drug related grade 3/4 
toxicity was reported in only 19% of the patients [60]. 
Combination therapies of ibrutinib with chemoimmuno- 
therapy are being evaluated in relapsed/refractory CLL 
patients targeting CD20 and the BCR pathway. High 
overall response rates as 90% and 100% were recently 
reported for the combinations PCI-32765/bendamus- 
tine/rituximab and PCI-32765/ofatumumab, respect- 
ively [60-61]. Both combinations were well tolerated. 
Another selective, irreversible and potent BTK 
inhibitor AVL-292-001 (CNX-774) has been tested and 
detected that, it inhibited and silenced BTK in 
preclinical studies and adapted to early clinical trials. A 
double-blind, placebo-controlled, single ascending 
dose study of AVL-292-001 in healthy volunteers 
demonstrated favorable safety, tolerability and 
pharmacokinetics of the drug [62]. A preliminary data 
from a phase Ib trial in CLL and B-NHL have been 
reported. In this trial, they reported that the drug was 
well tolerated and displayed the typical early effects of 
BCR inhibitors, including the initial rise in absolute 
lymphocyte counts and the simultaneous reduction in 
lymphadenopathy [63]. There are many other BTK 
inhibitors that are being preclinically tested such as 
GDC-0834, LFM-A13 and AVL-101 with no clinical 
studies yet [64]. 
1.3. Wnt/-Catenin/LEF-1 Signaling Pathway 
There is enhancing evidence that Wnt signaling 
pathway that is already known to play critical roles in 
various types of cancer has also essential functions in 
B cell neoplasia; especially CLL. Wnt signaling indeed 
involves three different pathways. The classical Wnt/-
catenin pathway- also named as canonical Wnt 
pathway, the frizzled regulated planar cell polarity 
pathway (PCP) and finally the Wnt/Ca
2+
 pathway [65- 
66].  
The classical canonical Wnt cascade plays critical 
roles in many developmental processes. It has also 
been included in development, regulation, proliferation 
and differentiation of T cell or B cell, [67-68] and also in 
the self-renewal of hematopoietic stem cells [69]. The 
transcription factors LEF/TCF (lymphoid enhancer 
binding factor/ T-cell factor) mediate a nuclear 
response to Wnt signals by interacting with -catenin. 
Wnt stimulation upregulates -catenin and by this 
approach -catenin cooperates with LEF-1. Following a 
Wnt signal, -catenin is stabilized and transported to 
the nucleus, where it binds to the LEF/TCF proteins to 
turn on Wnt target genes [70]. In the absence of a Wnt 
signal, although LEF/TCF proteins cannot activate 
target genes; a different type of -catenin is post- 
translationally regulated by binding to the cytoplasmic 
tail of the E-cadherin receptor, independent from Wnt 
signaling [71]. 
As we focus on the factors that contribute 
constitutive Wnt signaling in CLL, Wnt ligands and 
receptors come forward besides -Catenin and LEF-1. 
The Wnt gene family encodes secreted proteins that 
signal through cell surface receptors; which control 
development and responsible for malignant 
transformation in CLL [72]. A family member Wnt-3 is 
significantly overexpressed in CLL and has as the 
ability to induce proliferation of mouse pro B cells, 
which leads to transcriptional activation of LEF-1 [68]. 
Highly expressed Ror1 receptor binds to Wnt-5a and 
therefore activates NF-B; leading to enhanced 
survival of CLL cells [73]. Besides these, Wnt-10a and 
Table 1: Kinase Targeted Therapies in Clinical Trials for BCR Signaling in CLL  
Target Kinase Family  Function Inhibitor Phase  In Clinic 
LYN Src Activate and terminate BCR signaling Dasatinib II Yes 
SYK Syk/ZAP70 Upstream amplification of BCR signaling Fostamatinib II Yes 
PI3K Lipid kinase Intermediary in BCR signaling pathway Idelalisib II Yes 
AKT Akt Effect upon PI3K, phosphorylate downstream 
targets essential for B-cell proliferation 
Perifosine II Yes 
mTOR Serine/threonine kinase Downstream mediator of BCR signaling Everolimus I/II Combination therapy 
BTK Tec Downstream mediator of LYN/SYK in BCR 
signaling, roles in microenvironment interaction 
Ibrutinib II Yes 
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Wnt-16 were reported as the most abundant Wnt 
ligands expressed in CLL cells. However, Wnt-16 was 
also expressed in healthy B cells, but unlike Wnt-3, did 
not induce LEF-1-mediated transcription. In compar- 
ison to healthy B cells, CLL cells express higher levels 
of Wnt-3, Wnt-5b, Wnt-6, Wnt-10a and Wnt-14 ligands 
[74].  
As for -catenin; it takes place in cell-cell adhesion 
by interacting with the intracellular domain of E-
cadherin, besides functions as a central molecule in the 
Wnt signaling pathway [75]. -catenin based tumori- 
genesis in CLL comes out as a result of deregulation of 
-catenin signaling properties and subsequent 
activation of its downstream targets. The stability of -
catenin is influenced by several posttranslational 
regulators; such as E-cadherin, GSK-3, axin, conduc- 
ting and APC [76].  
LEF-1 is exclusively expressed transcription factor 
in transformed pre-B cell line; but its expression is 
rapidly downregulated in mature B cells [77]. LEF-1 
knockout mice exhibited reduced proliferation, 
differentiation, and increased apoptosis of pro-B220+ 
cells; establishing the data that LEF-1 has significant 
importance in B cell development [68]. 
1.3.1. Targeting Wnt/-Catenin/LEF-1 Signaling 
Pathway 
Several therapeutic approaches have been 
detected in order to inhibit Wnt signaling such as DNA 
demethylating agents, small molecules and non-
steroidal anti-inflammatory drugs. Negative regulator 
genes of the Wnt signaling pathway can be specified 
as secreted frizzled-related protein family members 
sFRP1, sFRP2, sFRP3, sFRP4, sFRP5, Wnt inhibitory 
factor-1 (WIF-1) and E-cadherin that undergo 
epigenetic silencing in CLL. The sFRPs are secreted 
glycoproteins that can competitively bind to Fzd 
(frizzeled related protein) receptors to form inactive 
receptor complexes; which in turn inhibit Wnt signaling 
[78]. WIF-1 competitively binds to Wnt ligands, 
rendering them incapable of binding to Fzd receptors 
and so acting as a negative modulator of the Wnt 
pathway [79]. E-cadherin is a receptor molecule 
involved in cell-cell adhesion and contains a -catenin 
binding domain. E-cadherin sequesters -catenin to the 
inner side of the cell membrane, thus inhibits its 
transactivation role in the nucleus. Loss of function 
mutations in the E-cadherin gene leads to cancer 
progression, invasion and metastasis [80]. The role of 
E-cadherin in hematologic malignancies was reported 
as that; E-cadherin expression was low or absent in 
CLL compared to healthy counterparts, due to hyper 
methylation at promoter region of E-cadherin [81]. 
Since epigenetic changes can be turned back by 
pharmacological agents; the demethylating compounds 
are promisingly used in order to inhibit endogenous 
methyl transferases to reactivate previously silenced 
genes. Thus usage of demethylating agents would be a 
promising strategy for treating CLL as an adjuvant to 
current drugs. The use of DNA demethylating agents 
named 5-azacytidine (AZA) and 5-aza-20-deoxycy- 
tidine (decitabine or DAC) has been established in the 
treatment of hematological malignancies [82]. There 
are two phase I clinical trials in progress using DAC 
agent [83] and AR-42 [84] in combination with chemo- 
therapy in CLL. 
Small molecules are also being used in order to 
modulate Wnt/-catenin signaling. Ethacrynic acid (EA) 
was previously shown to be cytotoxic upon CLL cells, 
but due to its diuretic side effects and lack of sufficient 
potency, it was not accepted as a novel therapeutic 
agent for CLL [85]. Afterwards, a research team 
produced 40 amide derivatives of ethacrynic acid in 
order to inhibit Wnt signaling and reduce CLL cell 
survival [86]. These agents achieved to alter Wnt 
reporter activity in functional in vitro studies but; driving 
mechanism has not been fully understood yet. Besides 
this, three compounds named “PKF115-584, 
CGP049090, and PKF222-815” were studied both in 
vitro and in vivo with promising results. These small 
molecules showed inhibition of LEF-1/-catenin target 
gene expression and induced apoptosis in primary CLL 
cells. Also the group reported significant in vivo tumor 
inhibition in xenograft tumor model without gross 
systemic toxicity [87]. Another identified small molecule 
inhibitor is, ICG-001, which downregulated -catenin/  
TCF/LEF signaling by binding to cyclic AMP response 
element binding protein (CBP). ICG-001 was demons- 
trated to selectively inhibit proliferation of transformed 
colon cancer cells in vitro and in vivo [88]. Recently it is 
found that ICG-001 leads to eradication of drug-resis- 
tant primary leukemia in combination with conventional 
therapy in vitro and significantly prolongs the survival of 
NOD/SCID mice engrafted with primary acute lympho- 
blastic leukemia (ALL). Therefore, specifically inhibiting 
CBP/catenin transcription represents a novel approach 
to overcome relapse in ALL [89]. But further investiga- 
tions are needed to evaluate the efficiency of ICG-001 
in a CLL disease model. Since small molecules have 
achieved Wnt signaling inhibition at sub-micromolar 
concentrations, such substances are potential candi- 
dates for monotherapy or in combination with standard 
chemotherapeutic agents currently used in CLL therapy. 
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Different non-steroidal anti-inflammatory drugs have 
been investigated in order to determine an agent 
capable of inhibiting the activity of -catenin-dependent 
reporter genes in malignant cell lines, by repressing -
catenin. One of these agents R-enantiomer (R-
etodolac, SDX-101) was shown to induce caspase-
mediated apoptosis in CLL cells in vitro. But due to 
high concentration of the determined IC50 dose; it 
doesn’t seem possible to take place in clinics because 
of high side effect risk [90]. Besides, etodolac-
derivatives SDX-101, SDX-308 and SDX-309 were 
reported as potential candidates for combination 
treatment of CLL; especially, SDX-308 in combination 
with chlorambucil [91].  
2. CHRONIC MYELOID LEUKEMIA 
2.1. Effects of BCR/ABL1 Fusion Oncoprotein on 
Proliferation and Survival of Leukemic Cells 
Hematopoietic CML cells that carry the Ph chromo- 
some results in BCR/ABL fusion gene; encoding 
p210
BCR/ABL 
oncoprotein. Unlike the normal p145 c-Abl, 
p210
BCR/ABL 
has constitutive tyrosine kinase activity and 
is predominantly localized in the cytoplasm. The tyro- 
sine kinase activity is essential for cellular transforma- 
tion and the cytoplasmic localization of BCR/ABL 
allows the assembly of phosphorylated substrates in 
protein complexes that transduce mitogenic and anti-
apoptotic signals. Ectopic expression of p210
BCR/ABL 
results in growth factor independence and leukemic 
transformation of immortal hematopoietic cells; that 
indicate a direct and causal role of BCR/ABL in CML 
pathogenesis. BCR/ABL overexpression activates 
numerous signal transduction pathways responsible for 
self-renewal, increase in genomic instability, triggering 
blockage in differentiation and reduced susceptibility to 
apoptosis of these malignant cells. Specifically, BCR-
ABL1 exerts its oncogenic activity through a complex 
network of pathways such as RAS/RAF/MAPK and 
JAK/STAT that promote proliferation and survival 
independent of the bone-marrow microenvironment 
[92]. BCR-ABL oncoprotein derived signaling interac- 
tions are summarized in Figure 2. 
2.2. RAS/RAF/MAPK Pathway and Treatment 
Strategies 
Several interactions have been identified between 
BCR-ABL and Ras. Autophosphorylation of Tyrosine 
177 within the BCR region of BCR-ABL1 provides a 
SH2-dependent docking site for the adapter molecule 
GRB-2 [93]. A GRB-2 effector molecule SOS (Son of 
Sevenless) is a guanine nucleotide exchange factor of 
RAS that mediates RAS activation [94]. When GRB-2 
binds to SOS protein, it stabilizes RAS in its active 
GTP-bound form. Two other adapter molecules, Shc 
and Crkl can also activate Ras. Both are substrates of 
BCR-ABL and bind BCR-ABL through their SH2 (Shc) 
or SH3 (Crkl) domains [95]. Ras activation is important 
for the pathogenesis of CML and there are biochemical 
evidence suggesting that BCR-ABL1 activates ERK 
through the activation of the RAS/RAF/MEK/ERK 
pathway. Raf initiates the cascade through the serine–
threonine kinases Mek1/Mek2 and Erk, which 
ultimately lead the activation of gene transcription [96]. 
The ERK1/2 pathway is constitutively activated in 
embryonic stem cells transformed by BCR-ABL1, and 
ERK2 activation may be involved in resistance to 
imatinib [97]. For treatment, inhibition of the RAS 
pathway by farnesyltransferase inhibitor BMS-214662 
exhibits synergy with MEK/ERK inhibitor PD184352 in 
the aim of suppressing proliferation and survival in 
K562 CML cell model and in primary chronic phase 
CD34+ CML cells. Finally, CML cell death was 
achieved, addition of a MEK inhibitor improved ability of 
BMS-214662 to selectively target CML stem/progenitor 
cells and accelerated relapse rate of the disease [98]. 
 
 
Figure 2: BCR-ABL oncoprotein derived signaling interac- 
tions in CML. 
Besides this MEK/ERK pathway, JNK pathway in 
the pathogenesis of BCR-ABL1-induced leukemoge- 
nesis needs some further investigation in order to 
determine the exact role. Some researchers suggest 
that activation of the JNK pathway promotes pro-
apoptotic signals in BCR-ABL1-expressing cells in 
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response to various agents (eg; arsenic trioxide and 
ceramide). While constitutive BCR-ABL1 kinase activity 
suppresses JNK activation; TKIs like imatinib 
redintegrate JNK phosphorylation which results in 
induced apoptosis [99]. However some other groups 
reported that activation of the JNK pathway by BCR-
ABL1 was required for malignant transformation and 
induced leukemogenesis [100]. Thus, inhibition of JNK 
ortholog Mapk8 (also known as JNK1) prevented BCR-
ABL1-mediated transformation both in vitro and in vivo 
[101]. In another study the authors reported that 
resveratrol promoted autophagic cell death in CML 
cells via JNK-mediated p62/SQSTM1 expression and 
JNK inhibition or p62 knockdown reversed resveratrol-
mediated autophagy and antileukemic effects [102]. In 
a recent study, effects of Icaritin (from Chinese herb 
medicine) was studied on CML cell model and 
concluded that; icaritin inhibited proliferation, induced 
apoptosis and promoted the erythroid differentiation of 
K562 cells. Besides, growth of Imatinib-resistant cells 
was suppressed and icaritin treated NOD-SCID nude 
mice lifespan was prolonged without suppression of 
bone marrow. Since icaritin up-regulate phospho-JNK 
or phospho-C-Jun and down-regulate phospho-ERK, 
the action of mechanism was attributed to regulation of 
BCR/ABL downstream signaling [103]. In a very recent 
study, Wnt5a was reported as imatinib efficacy 
enhancer through JNK/-catenin/Survivin pathway and 
when JNK activity was inhibited; influence of Wnt5a 
upon Imatinib effects was attenuated [104]. Together, 
these data suggest that the JNK pathway promotes 
diverse effects in BCR-ABL1 leukomogenesis and 
should be further studied.  
2.3. JAK/STAT Pathway and Treatment Strategies 
Janus Kinase/Signal Transducers and Activators of 
Transcription (JAK/STAT) pathway is one of the most 
important signaling pathways in the regulation of cell 
proliferation, survival and apoptosis which are activated 
by BCR/ABL. JAK/STAT signaling pathway includes 
JAK tyrosine kinases, STATs and suppressers of 
cytokine signaling (CIS/SOCS) families. Cytokines, 
hormones and growth factors are the ligands of 
JAK/STAT pathway and this pathway transduces 
signals into the nucleus driven from cytokine receptor. 
JAKs are stimulated by activation of a cytokine receptor 
which in turn activates STATs as transcription factors 
[105]. The first evidence for involvement of the JAK-
STAT pathway in CML pathogenesis came from 
studies in v-abl–transformed B cells [106]. Constitutive 
phosphorylation and activation of STAT transcription 
factors have been reported in BCR-ABL positive cell 
lines and in primary CML cells [107-108]. STAT 
proteins that take part in the activation or suppression 
of malignant transformations are STAT1 and STAT5. 
While STAT1 exerts an apoptosis inducer gene 
function, STAT5 is constitutively activated in various 
types of hematooncologic malignancies in which 
triggers the formation of leukemia named p210- and 
p190-transformed leukemic cells [109]. Overexpression 
of STATs, especially STAT5A provides an efficient 
mechanism to transduce an extracellular signal which 
results in posttranscriptional responses in hematolo- 
gical diseases [110]. Thus, STATs play important roles 
in anti-apoptotic activity mediated by Bcr-Abl [111]. 
Recent molecular biologic studies have revealed that in 
mice models, loss of STAT5 abolished CML-like 
leukemia induced by BCR-ABL1; pointing STAT5A/5B 
and the genes they activate as therapeutic targets for 
CML [112-113]. Inhibition of STAT5 phosphorylation 
has been shown to be an interesting target for 
eliminating leukemic stem cells [114]. 
To date, several curative strategies have been 
developed for CML, but the usage of first (imatinib), 
second (nilotinib, dasatinib) or third line (ponatinib: 
responsive to T315I mutation) tyrosine kinase inhibitors 
was a new generation therapy [115] till gain of resis- 
tance. Since then, specifically gene silencing studies 
have come out such as antisense oligonucleotides 
(ODN) or siRNA (small interfering RNA, RNAi) applica- 
tions. Also our group has demonstrated a number 
studies aimed to induce leukemic cell apoptosis due to 
RNAi-mediated gene-specific silencing of STAT5 that 
function as silent transcription factors but when 
activated, overexpressed and triggered leukemia 
development. In these studies we concluded that due 
to induced CML cell apoptosis following silencing of 
STAT5A; RNAi technology provided utility in vitro and 
will have contribution to clinics for both imatinib 
sensitive and resistant CML cells [116-118]. 
Besides these, in another study, effects of the 
BCR/ABL kinase inhibitors STI571 and adaphostin 
(NSC 680410) were determined on CML cells in vitro 
and finally the agents caused a synergistic effect since 
STAT5 phosphorylation was inhibited and apoptosis 
was induced [119]. In a more recent study, CML patient 
samples and a model cell line were treated with STAT5 
inhibitor sorafenib with nanomedicine applications. As a 
result, pSTAT5 and antiapoptotic protein MCL-1 
expressions were inhibited. This study revealed that, 
combining molecular diagnosis and personalized 
nanomedicines could have therapeutic functionality to 
endogenous proteins to overcome clinically important 
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challenges like molecular drug resistance [120]. All 
these studies point out the importance of STAT5 from 
JAK/STAT pathway in CML treatment. 
Besides STAT5, JAK2 is also activated in CML, but 
its direct role is not fully understood. It is well known 
that inhibition of JAK2 signalling reduces BCR-ABL and 
other downstream oncogenic signaling pathways [121]. 
Several inhibitors of JAK2 have been developed since 
the discovery that its inhibition overcame imatinib 
resistance by inducing apoptosis in imatinib-resistant 
cell lines. AG490, a potent and specific JAK2 inhibitor 
reduced BCR-ABL-induced oncogenicity and inhibited 
cell survival of imatinib-sensitive CML cell lines. AG490 
induced apoptosis also in imatinib-resistant CML cell 
[122] and also in CML diagnosed patients [123]. Other 
JAK2 inhibitors like TG101209 and HBC were shown to 
have clinical efficacy against CML cell lines and 
besides combination therapy of imatinib + HBC 
significantly induced apoptosis in CML cells [123]. A 
new dual kinase inhibitor for JAK2 and ABL kinases 
called ON044580 was recently discovered and was 
shown to target both imatinib-sensitive and resistant 
K562 CML cells [124]. By contrast, it has been shown 
in a recent study that JAK2 is dispensable for CML cell 
survival and maintenance in vitro and in vivo [125]. 
Since there are controversial findings about the impact 
of JAK2 upon CML, further investigation is still needed 
to confirm its access as a therapeutic target. 
3. CONCLUSIONS AND FUTURE DIRECTIONS  
The chronic leukemia is a holding promise for 
targeted therapies in cancer, in order to make a new 
era in cellular signaling pathways responsible for 
proliferation, survival, and self-renewal. Discovery of 
molecularly targeted drugs have dramatically enhanced 
the bad ending story of the disease. Besides traditional 
therapies, new and alternative mechanisms and agents 
are also being constantly investigated. While the 
strategy is to inhibit BCR signaling in CLL, the 
designed therapies are based on inhibiting BCR-ABL 
signaling in CML and inducing apoptosis for both. Till 
now, many successful treatments were achieved 
especially in CLL because of reflecting into clinic. 
Besides TKIs; many other promising agents are being 
investigated for CML. The identification of driving 
pathway in CML stem cells that can be targeted could 
solve the problem of minimal residual disease and 
potentially cure CML suffering patients. With the 
development of more efficiently signaling pathways 
targeted agents and mouse modeling studies, it may 
become possible to make progress towards 
individualized therapy with longer remissions and even 
cures in chronic leukemias. 
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